Latest & greatest articles for pioglitazone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pioglitazone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pioglitazone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pioglitazone

1. Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone 29934374 2018 08 17 1524-4539 2018 Jun 22 Circulation Circulation Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone. CIRCULATIONAHA.118.034763 10.1161/CIRCULATIONAHA.118.034763 Background -The Insulin Resistance Intervention after Stroke (IRIS) trial demonstrated that pioglitazone reduced risk for both (...) cardiovascular events and diabetes in insulin resistant patients. However, concern remains that pioglitazone may increase risk for heart failure (HF) in susceptible individuals. Methods -In IRIS, patients with insulin resistance but without diabetes were randomized to pioglitazone or placebo (1:1) within 180 days of an ischemic stroke or TIA and followed for up to 5 years. To identify patients at higher HF risk with pioglitazone we performed a secondary analysis of IRIS participants without HF history at

EvidenceUpdates2018

2. Pioglitazone

Pioglitazone Top results for pioglitazone - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pioglitazone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)

Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke) 29084736 2018 02 07 1524-4539 137 5 2018 Jan 30 Circulation Circulation Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). 455-463 10.1161/CIRCULATIONAHA (...) .117.030458 The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack. The current planned secondary analysis uses updated 2013 consensus criteria for ischemic stroke to examine the effect of pioglitazone on stroke outcomes. Participants were randomly assigned to receive pioglitazone (45 mg/d

EvidenceUpdates2018

4. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. BACKGROUND: Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia occurs secondary to insulin resistance and is associated with increased risk of cardiovascular disease and diabetes mellitus. Insulin-sensitising agents (...) combined data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). We assessed statistical heterogeneity using the I 2 statistic and reported quality of the evidence for primary outcomes using GRADE methodology. MAIN RESULTS: We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-inositol, rosiglitazone and pioglitazone. We compared these with each other, placebo or no treatment. We included 48 studies (4451 women), 42 of which

Cochrane2017

5. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial

Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial 28939682 2017 09 23 2017 11 14 1468-330X 2017 Sep 22 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. jnnp-2017-316361 10.1136/jnnp-2017-316361 Patients with cerebrovascular disease are at increased risk (...) for cognitive dysfunction. Modification of vascular risk factors, including insulin resistance, could improve poststroke cognitive function. In the Insulin Resistance Intervention after Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) were randomised to pioglitazone (target 45 mg daily) or placebo. All patients were insulin resistant based on a Homeostasis Model Assessment-Insulin Resistance score >3.0. For this preplanned analysis of cognitive function, we

EvidenceUpdates2017

6. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT.

Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. 28331909 2017 03 23 2017 04 03 2476-4108 14 12 2016 Dec International journal of reproductive biomedicine (Yazd, Iran) Int J Reprod Biomed (Yazd) Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. 743-754 Insulin resistance and hyperinsulinemia may play (...) a role in pathogenesis of PCOS. One of the common therapeutic methods is using insulin-sensitizing drugs such as metformin and thiazolidinediones. The purpose was to determine the effect of metformin and pioglitazone on clinical, hormonal and metabolic parameters in women with PCOS. Eighty four women randomly received one of the following for 3 months: metformin (n=28) (500 mg three times a day), pioglitazone (30 mg daily) (n=28) and combination of both metformin and pioglitazone (n=28) (30 mg/day

International journal of reproductive biomedicine (Yazd, Iran)2017

7. Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial

Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial | Clinical Correlations Gamechanger? Can Pioglitazone Reduce Cardiovascular Events After a Stroke? An Analysis of the IRIS Trial January 19, 2017 By Johanna Hase, MD Peer Reviewed Welcome to Gamechangers, a series that takes a critical look at the latest in medical literature to answer (...) risk of another stroke. Assuming you are already managing her HLD and HTN, what are your options? Would a thiazolidinedione (pioglitazone) decrease her risk of stroke? Why does this matter? Even with optimal medical therapy, survivors of [1], and over 50% of non-diabetic [2]. The Prospective Pioglitazone Clinical Trail in Macrovascular Events (PROactive) showed that in diabetics with cardiovascular disease, patients [3,4]. This is postulated to be due to its effects on the PPAR-γ and PPAR-α

Clinical Correlations2017

8. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532845 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):704. doi: 10.1056/NEJMc1605904. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27532845 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms

NEJM2016

9. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532846 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):702-3. doi: 10.1056/NEJMc1605904#SA1. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 1 . 1 Hadassah-Hebrew University Medical Center, Jerusalem, Israel bursz@mail.huji.ac.il. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27532846 DOI: [Indexed

NEJM2016 Full Text: Link to full Text with Trip Pro

10. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532847 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):703. doi: 10.1056/NEJMc1605904#SA2. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 1 , 2 . 1 Charité Universitätsmedizin Berlin, Berlin, Germany wolfram.doehner@charite.de. 2 University Medical Center Göttingen, Göttingen, Germany. Comment in [N Engl J Med. 2016

NEJM2016 Full Text: Link to full Text with Trip Pro

11. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532848 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):703-4. doi: 10.1056/NEJMc1605904#SA3. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. 1 , 1 , 2 . 1 Huashan Hospital, Shanghai, China khu3@mgh.harvard.edu. 2 Massachusetts General Hospital, Boston, MA. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID

NEJM2016 Full Text: Link to full Text with Trip Pro

12. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. OBJECTIVE: To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. DESIGN: Retrospective cohort study using propensity score matched cohorts. SETTINGS: Healthcare databases from Finland, the Netherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records (...) on prescriptions, hospitals, general practitioners, cancer, and deaths. PARTICIPANTS: Patients with type 2 diabetes who initiated pioglitazone (n=56 337) matched with patients with type 2 diabetes in the same country exposed to diabetes drug treatments other than pioglitazone (n=317 109). Two matched cohorts were created, using a 1:1 fixed ratio (nearest match cohort) and a 1:10 variable ratio (multiple match cohort). Patients were matched on treatment history and propensity scores accounting for several

BMJ2016

14. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. 27322798 2016 09 06 2017 05 04 2017 05 04 1539-3704 165 5 2016 Sep 06 Annals of internal medicine Ann. Intern. Med. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. 305-15 10.7326/M15-1774 The metabolic defects of nonalcoholic steatohepatitis (...) (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). University hospital. Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from

Annals of Internal Medicine2016

15. Pioglitazone use and risk of bladder cancer: population based cohort study.

Pioglitazone use and risk of bladder cancer: population based cohort study. OBJECTIVE: To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes. DESIGN: Population based cohort study. SETTING: General practices contributing data to the United Kingdom Clinical Practice Research Datalink. PARTICIPANTS: A cohort of 145,806 patients newly treated with antidiabetic drugs between 1 January 2000 (...) and 31 July 2013, with follow-up until 31 July 2014. MAIN OUTCOME MEASURES: The use of pioglitazone was treated as a time varying variable, with use lagged by one year for latency purposes. Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% confidence intervals of incident bladder cancer associated with pioglitazone overall and by both cumulative duration of use and cumulative dose. Similar analyses were conducted for rosiglitazone, a thiazolidinedione

BMJ2016

16. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. BACKGROUND: Patients with ischemic stroke or transient ischemic attack (TIA) are at increased risk for future cardiovascular events despite current preventive therapies. The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease. METHODS: In this multicenter, double (...) -blind trial, we randomly assigned 3876 patients who had had a recent ischemic stroke or TIA to receive either pioglitazone (target dose, 45 mg daily) or placebo. Eligible patients did not have diabetes but were found to have insulin resistance on the basis of a score of more than 3.0 on the homeostasis model assessment of insulin resistance (HOMA-IR) index. The primary outcome was fatal or nonfatal stroke or myocardial infarction. RESULTS: By 4.8 years, a primary outcome had occurred in 175 of 1939

NEJM2016

17. Pioglitazone and Alzheimers Disease, a Possible Treatment and Preventative Modality

Pioglitazone and Alzheimers Disease, a Possible Treatment and Preventative Modality "Pioglitazone and Alzheimers Disease, a Possible Treatment and Preventa" by Jeffrey C. Otis < > > > > > Title Author Date of Award Summer 8-8-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background : Alzheimers disease is common and debilitating, and diabetes is a widely documented risk factor for the development of Alzheimers disease. Given (...) that Alzheimers disease and diabetes are two extremely common and comorbid conditions in geriatric populations that greatly affect quality of life, it follows that treatment and prevention of both pathologies be exhaustively investigated. This is especially evident, as there is no existing medication that prevents or reverses the pathogenesis of Alzheimers disease. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonists of the thiazolidinedione drug class, acts by up-regulating gene

Pacific University EBM Capstone Project2016

18. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone 24528605 2014 04 16 2015 01 23 2016 12 15 1463-1326 16 5 2014 May Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. 467-77 10.1111/dom.12273 The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated (...) in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

19. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial 23906415 2014 08 18 2015 05 12 2015 06 15 1463-1326 16 2 2014 Feb Diabetes, obesity & metabolism Diabetes Obes Metab Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo (...) -controlled trial. 147-58 10.1111/dom.12188 This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM). Patients with HbA1c ≥7 and ≤10% were randomized and treated with once daily empagliflozin 10 mg (n = 165), empagliflozin 25 mg (n = 168) or placebo (n = 165) as add-on to pioglitazone ± metformin for 24 weeks. Endpoints included changes from baseline in HbA1c (primary endpoint), fasting plasma glucose (FPG

EvidenceUpdates2013

20. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial

Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial 23380864 2013 02 05 2013 06 20 2013 11 21 1534-6080 95 3 2013 Feb 15 Transplantation Transplantation Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. 456-62 10.1097/TP.0b013e318276a20e New-onset diabetes after transplantation (NODAT) is (...) pioglitazone, or placebo for 3 months in addition to lifestyle counseling. Outcome measures were difference in change in oral glucose tolerance test between the groups and between baseline and end of study as well as change in HbA1c, serum lipids, and renal and hepatic function. In both treatment groups, 2-hr plasma glucose at 3 months was significantly reduced compared with baseline (vildagliptin: -20±24 mg/dL; P=0.002 and pioglitazone: -23±29 mg/dL; P=0.004), and pioglitazone also significantly improved

EvidenceUpdates2013